Climb Bio Inc
NASDAQ:CLYM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Climb Bio Inc
NASDAQ:CLYM
|
US |
|
Fashionette AG
XETRA:FSNT
|
DE |
|
Whispir Ltd
ASX:WSP
|
AU |
|
SKF AB
STO:SKF B
|
SE |
|
B
|
Bioton SA
WSE:BIO
|
PL |
|
Z
|
Zhejiang Jasan Holding Group Co Ltd
SSE:603558
|
CN |
|
W
|
Winson Holdings Hong Kong Ltd
HKEX:6812
|
HK |
|
Shanghai Rural Commercial Bank Co Ltd
SSE:601825
|
CN |
|
M
|
MMC Sanayi ve Ticari Yatirimlar AS
IST:MMCAS.E
|
TR |
|
P
|
Pensana PLC
F:48W
|
UK |
|
Whirlpool Corp
NYSE:WHR
|
US |
|
OPKO Health Inc
NASDAQ:OPK
|
US |
|
STMicroelectronics NV
MIL:STMMI
|
NL |
|
E2E Networks Ltd
NSE:E2E
|
IN |
Climb Bio Inc
Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial.
Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial.
